Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 4,270 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood samples collected Clear all
Recruiting Not applicable Interventional

Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis

NCT05844865
View directory record Official record
Conditions
Peritoneal Carcinomatosis, Gastrointestinal Peritoneal Carcinomatosis
Interventions
Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting Phase 2 Interventional

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT07510334
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Nivolumab, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting Phase 2 Interventional

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

NCT05595499
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Fisetin, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Trima Version 7.0 Platelets in 100% Plasma

NCT02754492
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Trima Accel System with Version 7.0 Software
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 28, 2026, 4:06 PM EDT
Active, not recruiting Early Phase 1 Interventional

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

NCT05358938
View directory record Official record
Conditions
Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
Exercise, Checkpoint Blockade, Immune
Other · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational

Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

NCT04188912
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Biospecimen Collection, Optical Coherence Tomography, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Medical Chart Review
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Gainesville, Florida • Tampa, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting No phase listed Observational

Role of Gut Microbiome in Cancer Therapy

NCT05112614
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting No phase listed Observational

Mechanisms Underlying Impaired Diabetic Wound Healing

NCT00777712
View directory record Official record
Conditions
Non-healing Wound
Interventions
Blood draw
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

NCT02282514
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting Phase 2 Interventional

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

NCT05799144
View directory record Official record
Conditions
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
Interventions
DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging, Biopsy
Biological · Procedure
Lead sponsor
Michael K. Gibson
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Birmingham, Alabama • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational

Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma

NCT02541123
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Blood draw
Other
Lead sponsor
Banyan Biomarkers, Inc
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Gainesville, Florida • Orlando, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 28, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

NCT04840979
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-florbetaben
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Autonomic Control of the Circulation and VDR

NCT03513770
View directory record Official record
Conditions
Venous Distension Reflex, Blood Pressure
Interventions
Wrist-to-elbow (W-E) occlusion, ketorolac tromethamine, saline control
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225
View directory record Official record
Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk
Procedure · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
409
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

NCT03647917
View directory record Official record
Conditions
Skin Aging of Face and Hands
Interventions
Platelet Rich Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 28, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pro-rEsolving and pRo-inflammatory reSPonses to Acute exhaustIve exeRcisE in Healthy Individuals

NCT05923125
View directory record Official record
Conditions
Exercise
Interventions
Graded-Intensity Treadmill Exercise Protocol
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study Freeze and Transport Immune Cells

NCT00138268
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Pertussis, Poliomyelitis, Tetanus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 28, 2026, 4:06 PM EDT
Suspended Phase 2Phase 3 Interventional

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

NCT01810913
View directory record Official record
Conditions
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
Drug · Procedure · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
338
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

NCT04267120
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Research blood collection
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Palo Alto, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational

Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer

NCT01688323
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Collect Blood and Survey Instruments
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 28, 2026, 4:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

NCT01208662
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Paul Richardson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

NCT01472627
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Blood draws
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 28, 2026, 4:06 PM EDT
Not yet recruiting Phase 2 Interventional

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

NCT07390968
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)

NCT00178659
View directory record Official record
Conditions
Brain Injuries, Traumatic, Traumatic Brain Injury
Interventions
Blood/saliva samples for protein/molecular analysis
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 4:06 PM EDT